660 related articles for article (PubMed ID: 15274306)
21. Effect of nomegestrol acetate on human estrogen sulfotransferase activity in the hormone-dependent MCF-7 and T-47D breast cancer cell lines.
Chetrite GS; Paris J; Shields-Botella J; Philippe JC; Pasqualini JR
Anticancer Res; 2003; 23(6C):4651-5. PubMed ID: 14981909
[TBL] [Abstract][Full Text] [Related]
22. Control of sulfatase and sulfotransferase activities by medrogestone in the hormone-dependent MCF-7 and T-47D human breast cancer cell lines.
Chetrite GS; Ebert C; Wright F; Philippe AC; Pasqualini JR
J Steroid Biochem Mol Biol; 1999; 70(1-3):39-45. PubMed ID: 10529001
[TBL] [Abstract][Full Text] [Related]
23. Inhibition of estrone sulfatase and proliferation of human breast cancer cells by nonsteroidal (p-O-sulfamoyl)-N-alkanoyl tyramines.
Selcer KW; Hegde PV; Li PK
Cancer Res; 1997 Feb; 57(4):702-7. PubMed ID: 9044848
[TBL] [Abstract][Full Text] [Related]
24. The selective estrogen enzyme modulators in breast cancer: a review.
Pasqualini JR
Biochim Biophys Acta; 2004 Jun; 1654(2):123-43. PubMed ID: 15172700
[TBL] [Abstract][Full Text] [Related]
25. Inhibition of oestrone sulphatase activity by tibolone and its metabolites.
Purohit A; Malini B; Hooymans C; Newman SP
Horm Metab Res; 2002 Jan; 34(1):1-6. PubMed ID: 11832993
[TBL] [Abstract][Full Text] [Related]
26. Breast cancer and steroid metabolizing enzymes: the role of progestogens.
Pasqualini JR
Maturitas; 2009 Dec; 65 Suppl 1():S17-21. PubMed ID: 19962254
[TBL] [Abstract][Full Text] [Related]
27. Differential effects of progestogens, by type and regimen, on estrogen-metabolizing enzymes in human breast cancer cells.
Xu B; Kitawaki J; Koshiba H; Ishihara H; Kiyomizu M; Teramoto M; Kitaoka Y; Honjo H
Maturitas; 2007 Feb; 56(2):142-52. PubMed ID: 16962266
[TBL] [Abstract][Full Text] [Related]
28. The anti-aromatase effect of progesterone and of its natural metabolites 20alpha- and 5alpha-dihydroprogesterone in the MCF-7aro breast cancer cell line.
Pasqualini JR; Chetrite G
Anticancer Res; 2008; 28(4B):2129-33. PubMed ID: 18751385
[TBL] [Abstract][Full Text] [Related]
29. Inhibition of estrone sulfatase activity by estrone-3-methylthiophosphonate: a potential therapeutic agent in breast cancer.
Duncan L; Purohit A; Howarth NM; Potter BV; Reed MJ
Cancer Res; 1993 Jan; 53(2):298-303. PubMed ID: 8417823
[TBL] [Abstract][Full Text] [Related]
30. Reductive 17beta-hydroxysteroid dehydrogenases in the sulfatase pathway: critical in the cell proliferation of breast cancer.
Aka JA; Mazumdar M; Lin SX
Mol Cell Endocrinol; 2009 Mar; 301(1-2):183-90. PubMed ID: 19038308
[TBL] [Abstract][Full Text] [Related]
31. Selective estrogen enzyme modulator actions of melatonin in human breast cancer cells.
Gonzalez A; Cos S; Martinez-Campa C; Alonso-Gonzalez C; Sanchez-Mateos S; Mediavilla MD; Sanchez-Barcelo EJ
J Pineal Res; 2008 Aug; 45(1):86-92. PubMed ID: 18298468
[TBL] [Abstract][Full Text] [Related]
32. Differential effects of progestins on breast tissue enzymes.
Pasqualini JR
Maturitas; 2003 Dec; 46 Suppl 1():S45-54. PubMed ID: 14670645
[TBL] [Abstract][Full Text] [Related]
33. Stilbene-based inhibitors of estrone sulfatase with a dual mode of action in human breast cancer cells.
Walter G; Liebl R; von Angerer E
Arch Pharm (Weinheim); 2004 Dec; 337(12):634-44. PubMed ID: 15597397
[TBL] [Abstract][Full Text] [Related]
34. New development in intracrinology of breast carcinoma.
Sasano H; Suzuki T; Nakata T; Moriya T
Breast Cancer; 2006; 13(2):129-36. PubMed ID: 16755106
[TBL] [Abstract][Full Text] [Related]
35. Biochemical and biological evaluation of novel potent coumarin inhibitor of 17β-HSD type 1.
Starčević S; Kocbek P; Hribar G; Rižner TL; Gobec S
Chem Biol Interact; 2011 May; 191(1-3):60-5. PubMed ID: 21232530
[TBL] [Abstract][Full Text] [Related]
36. Estrone sulfate-sulfatase and 17 beta-hydroxysteroid dehydrogenase activities: a hypothesis for their role in the evolution of human breast cancer from hormone-dependence to hormone-independence.
Pasqualini JR; Chetrite G; Nguyen BL; Maloche C; Delalonde L; Talbi M; Feinstein MC; Blacker C; Botella J; Paris J
J Steroid Biochem Mol Biol; 1995 Jun; 53(1-6):407-12. PubMed ID: 7626488
[TBL] [Abstract][Full Text] [Related]
37. Binary and ternary crystal structure analyses of a novel inhibitor with 17beta-HSD type 1: a lead compound for breast cancer therapy.
Mazumdar M; Fournier D; Zhu DW; Cadot C; Poirier D; Lin SX
Biochem J; 2009 Dec; 424(3):357-66. PubMed ID: 19929851
[TBL] [Abstract][Full Text] [Related]
38. Oxidations of 17beta-estradiol and estrone and their interconversions catalyzed by liver, mammary gland and mammary tumor after acute and chronic treatment of rats with indole-3-carbinol or beta-naphthoflavone.
Ritter CL; Prigge WF; Reichert MA; Malejka-Giganti D
Can J Physiol Pharmacol; 2001 Jun; 79(6):519-32. PubMed ID: 11430590
[TBL] [Abstract][Full Text] [Related]
39. 17beta-hydroxysteroid dehydrogenases in human breast cancer.
Nagasaki S; Miki Y; Akahira J; Suzuki T; Sasano H
Ann N Y Acad Sci; 2009 Feb; 1155():25-32. PubMed ID: 19250189
[TBL] [Abstract][Full Text] [Related]
40. Effect of tibolone (Org OD14) and its metabolites on estrone sulphatase activity in MCF-7 and T-47D mammary cancer cells.
Chetrite G; Kloosterboer HJ; Pasqualini JR
Anticancer Res; 1997; 17(1A):135-40. PubMed ID: 9066643
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
